WO2001076583A1 - Synergistic compositions containing choline base and succinic acid for insulin resistance and diabetes - Google Patents
Synergistic compositions containing choline base and succinic acid for insulin resistance and diabetes Download PDFInfo
- Publication number
- WO2001076583A1 WO2001076583A1 PCT/RU2000/000122 RU0000122W WO0176583A1 WO 2001076583 A1 WO2001076583 A1 WO 2001076583A1 RU 0000122 W RU0000122 W RU 0000122W WO 0176583 A1 WO0176583 A1 WO 0176583A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- succinic acid
- mammal
- choline
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- This invention relates to compositions and methods for achieving a synergistic effect in treating insulin resistance and diabetes mellitus in a mammal. More specifically, this invention relates to synergistic composition comprising amounts of choline base or a pharmaceutically acceptable salt thereof and succinic acid or a pharmaceutically acceptable salt thereof, which are presented in amounts sufficient to cause synergistic effects in treating insulin resistance and diabetes mellitus in a mammal.
- this invention relates to methods for achieving a synergistic effects in treating insulin resistance and diabetes mellitus in a mammal, which methods comprise administering to said mammal, either stepwise or simultaneously, effective amounts of choline base or a pharmaceutically acceptable salt thereof and succinic acid or a pharmaceutically acceptable salt thereof. Further, this invention relates to a novel derivative of choline.
- this invention relates to bis(2-hydroxy-N,N,N-trimethylethanaminium) succinate, the novel salt of choline formed by choline base and succinic acid in the molar ratio 2: 1 , a process for producing the salt, and use of the salt in medicine, preferably for the manufacture of a medicament for treating insulin resistance, hyperlipidemia, dyslipidemia, or diabetes mellitus.
- Insulin is the major anabolic hormone in the body and has multiple effects on a variety of tissues. Insulin stimulates the glucose uptake in muscle and fat and inhibits the glucose release from the liver. In addition, insulin regulates both plasma and tissue lipid metabolism, protein synthesis, cell growth and electrolyte balance. 0 Insulin resistance is defined as an impaired biological response to either exogenous or endogenous insulin. The measured biological responses could reflect metabolic processes such as changes in carbohydrate, lipid or protein metabolism as well as mitogenic processes such as alterations in growth, differentiation, DNA synthesis, and regulation of gene transcription.
- Insulin resistance has clearly emerged as an important cause of glucose intolerance leading to type 2 diabetes and a cluster of abnormalities, including hyperlipidemia and dyslipidemia, high blood pressure, hyperuricemia, and a decrease in plasma fibrinolytic activity. Reaven, G. M. Physiol-Rev. 75(3): 473-86 (1995); "Consensus development conference on insulin resistance", Diabetes Care. 21 (2) 1998.
- Insulin resistance can be associated with a variety of disease states such as gestational diabetes mellitus, obesity, ageing, atherosclerosis, cardiovascular syndrome X, AIDS, cancer, wasting/cachexia, sepsis, trauma associated with burns, malnutrition, lupus and other autoimmune diseases, endocrine diseases, polycystic ovary syndrome, or complications arising from athletic activity.
- disease states such as gestational diabetes mellitus, obesity, ageing, atherosclerosis, cardiovascular syndrome X, AIDS, cancer, wasting/cachexia, sepsis, trauma associated with burns, malnutrition, lupus and other autoimmune diseases, endocrine diseases, polycystic ovary syndrome, or complications arising from athletic activity.
- insulin resistance manifesting itself in pathologically elevated fasting plasma insulin levels and can be assessed by measurement of insulin concentration in plasma.
- diabetes mellitus describes a metabolic disorder of multiple aetiology characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Clinically, diabetes mellitus manifesting itself in pathologically elevated plasma glucose levels and can be assessed by measurement of glucose concentration in blood.
- succinic acid was described in JP patent 6062798 as a component of food for person with poor glucose-tolerance in combination with acetic, lactic, and gluconic acid.
- Disodium succinate was described as a component of the composition for decreasing blood glucose in rabbits with alloxan diabetes in combination with citric and acetic acid. Dzvonkevich, N.D. et al., Ukr. Biokhim. Zh.. 46(5):547-552(1974).
- Monocholine succinate the acid salt formed by choline base and succinic acid in the molar ratio 1 :1 , was described in US patent 5,124,061 as a component of plant cryoprotectant composition.
- this salt has not been obtained as the product with reproducible properties and was defined only by reference to process in which choline base and succinic acid were entered in molar ratio 1 :1. Acidity of monocholine succinate and absence of reproducible properties restricts the use of the described monocholine succinate in medicine.
- This invention relates to compositions and methods for achieving a synergistic effect in treating insulin resistance and diabetes mellitus in a mammal. More specifically, this invention relates to synergistic composition comprising amounts of choline base or a pharmaceutically acceptable salt thereof and succinic acid or a pharmaceutically acceptable salt thereof, which are presented in amounts sufficient to cause synergistic effects in treating insulin resistance and diabetes mellitus in a mammal. Further, this invention relates to methods for achieving a synergistic effects in treating insulin resistance and diabetes mellitus in a mammal, which methods comprise administering to said mammal, either stepwise or simultaneously, effective amounts of choline base or a pharmaceutically acceptable salt thereof and succinic acid or a pharmaceutically acceptable salt thereof.
- this invention relates to a novel derivative of choline. More specifically, this invention relates to bis(2-hydroxy-N,N,N-trimethylethanaminium) succinate, the novel salt of choline formed by choline base and succinic acid in the molar ratio 2:1 , a process for producing the salt, and use of the salt in medicine, preferably for the manufacture of a medicament for treating insulin resistance, hyperlipidemia, dyslipidemia, or diabetes mellitus.
- treating means the management and care of a mammal for the purpose of combating the disease, condition, or disorder and includes the administration of choline base or a pharmaceutically acceptable salt thereof and succinic acid or a pharmaceutically acceptable salt thereof to prevent the onset of the symptoms or complications, alleviating the symptoms or complications, or eliminating the disease, condition, or disorder
- Treating insulin resistance includes increasing insulin sensitivity in a mammal and other effects, which are resulted from increasing insulin sensitivity in a mammal Such effects include, but are not limited to improving in carbohydrate, lipid, or protein metabolism, alterations in growth, differentiation, DNA synthesis, and regulation of gene transcription
- the present invention provides a method for achieving a synergistic effect in treating insulin resistance in a mammal in need thereof, which comprises administering to said mammal an effective amounts of choline base or a pharmaceutically acceptable salt thereof and succinic acid or a pharmaceutically acceptable salt thereof Preferred effect achieved according to this invention in treating insulin resistance is lowering pathologically elevated plasma insulin levels
- Insulin resistance in the mammal can be associated with disorders such as diabetes mellitus and its chronic complications, gestational diabetes mellitus, impaired glucose tolerance, obesity, ageing, atherosclerosis, syndrome X, cardiovascular disease, AIDS, cancer, wasting/cachexia, sepsis, trauma associated with burns, malnutrition, lupus and other autoimmune diseases, endocrine diseases, hyperu ⁇ cemia, hyperlipidemia, dyslipidemia, polycystic ovary syndrome, or complications arising from athletic activity
- insulin resistance is associated with diabetes mellitus in the mammal
- the present invention provides a method for achieving a synergistic effect in treating diabetes mellitus in a mammal in need thereof, which comprises administering to said mammal an effective amounts of choline base or a pharmaceutically acceptable salt thereof and succinic acid or a pharmaceutically acceptable salt thereof Preferred effect achieved according to this invention in treating diabetes mellitus is lowering pathologically elevated blood glucose levels
- choline base or a pharmaceutically acceptable salt thereof of the invention is choline chloride
- succinic acid or a pharmaceutically acceptable salt thereof of the invention is disodium succinate
- choline base or a pharmaceutically acceptable salt thereof and succinic acid or a pharmaceutically acceptable salt thereof can be stepwise in time or simultaneous with the simultaneous method being preferred.
- Choline base or a pharmaceutically acceptable salt thereof can be administered orally, parenterally, topically, or rectally.
- choline base or a pharmaceutically acceptable salt thereof is administered parenterally.
- Succinic acid or a pharmaceutically acceptable salt thereof can be administered orally, parenterally, topically, or rectally.
- succinic acid or a pharmaceutically acceptable salt thereof is administered parenterally.
- the choline base or a pharmaceutically acceptable salt thereof is administered for a period of 1 day or longer, more preferably for a period of 3 to 7 days.
- the succinic acid or pharmaceutically acceptable salt thereof is administered for a period of 1 day or longer, more preferably for a period of 3 to 7 days.
- the present invention provides a composition for achieving a synergistic effect in treating insulin resistance in a mammal in need thereof, which comprises an effective amounts of choline base or a pharmaceutically acceptable salt thereof and succinic acid or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.
- Preferred effect achieved according to this invention in treating insulin resistance is lowering pathologically elevated plasma insulin levels.
- the present invention provides a composition for achieving a synergistic effect in treating diabetes mellitus in a mammal in need thereof, which comprises an effective amounts of choline base or a pharmaceutically acceptable salt thereof and succinic acid or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.
- Preferred effect achieved according to this invention in treating diabetes mellitus is lowering pathologically elevated blood glucose levels.
- the pharmaceutically acceptable salt of the choline base is prepared by known methods from nontoxic organic and inorganic acids.
- Such acids include, but are not limited to, hydrogen chloride, hydrogen bromide, citric acid, tarta c acid, and succinic acid.
- choline base or a pharmaceutically acceptable salt thereof of the invention is choline chloride.
- the pharmaceutically acceptable salt of the succinic acid is prepared by known methods from organic and inorganic bases.
- bases include, but are not limited to, nontoxic alkali metal and alkaline earth bases, for example, calcium, lithium, sodium, and potassium hydroxide; ammonium hydroxide and nontoxic organic bases, such as triethylamine, butylamine, diethanolamine, triethanolamine, and choline base.
- succinic acid or a pharmaceutically acceptable salt thereof of the invention is disodium succinate.
- suitable carriers and diluents include lactose, dextrose, sorbitol, mannitol, calcium phosphate, alginates, gelatin, calcium silicate, microcrystalline cellulose, methylcellulose, polyvinylpyrrolidone, water, methyl- and propylhydroxybenzoates, talc, magnesium stearate, stearic acid, and mineral oil.
- the compositions of the invention can additionally include lubricating agents, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents, or flavoring agents.
- compositions of the invention can be administered in a wide variety of different dosage forms, i.e., they may be formulated with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, aqueous solutions, elixirs, syrups and the like.
- the effective amount of choline base or a pharmaceutically acceptable salt thereof for use in the methods and compositions of this invention is preferably from 3 to 300 mg per day per kg of body weight of the mammal.
- the effective amount of succinic acid or a pharmaceutically acceptable salt thereof for use in the methods and compositions of this invention is preferably from 1 to 250 mg per day per kg of body weight of the mammal.
- the present invention provides bis(2-hydroxy-N,N,N- thmethylethanaminium) succinate, which has the chemical formula given below:
- N,N,N-trimethylethanaminium) succinate which comprises reacting choline base with succinic acid in the presence of water, alcohol, or mixture thereof.
- bis(2-hydroxy-N,N,N-trimethylethanaminium) succinate is prepared by reacting the choline base and succinic acid, wherein the mole ratio of choline base to succinic acid entered in reaction is about 2:1 , but no lower than 1.9:1 and no higher than 2.1 :1.
- the reaction take place at ambient temperatures and the reaction is quantitative.
- the desired product is obtained as a white crystalline powder with reproducible properties.
- bis(2- hydroxy-N,N,N-trimethylethanaminium) succinate in medicine, preferably for the manufacture of a medicament for treating insulin resistance, hyperlipidemia, dyslipidemia, and diabetes mellitus in a mammal in need thereof.
- Preferred effect achieved according to this invention in treating insulin resistance is lowering pathologically elevated plasma insulin levels.
- Preferred effects achieved according to this invention in treating hyperlipidemia are lowering pathologically elevated plasma triglycerides and cholesterol levels.
- Preferred effects achieved according to this invention in treating dyslipidemia are lowering low-density lipoprotein cholesterol levels and increasing high- density lipoprotein cholesterol levels.
- Preferred effect achieved according to this invention in treating diabetes mellitus is lowering pathologically elevated blood glucose levels.
- This example shows the synergistic effects in treating insulin resistance and diabetes mellitus achieved by co-administration of effective amounts of choline chloride and disodium succinate to diabetic rats.
- Plasma insulin concentrations were determined using a kit ("Dako", Dutch) with a rat insulin standard (Novo Research Institute, Bagsvard, Denmark). Plasma glucose concentrations were determined using a kit ("Agat”, Russia). Plasma triglycerides and cholesterol concentrations were determined with reagents FS, "DiaSys”, Germany; HDL cholesterol with reagents “Cormay”, Tru; and LDL cholesterol with reagents "Boehringer Mannheim", Germany.
- mice Male Wistar rats 8-10 weeks of age 210-230g of body weight were used. The rats were housed at the temperature of 18 ⁇ 21°C on a 12 hour light-dark cycle. Rats were fed on a stock laboratory diet (59 % carbohydrates; 17 % protein; 3 % fat; 21 % minerals, water, and cellulose) and allowed water ad libitum. Diabetes mellitus was induced in Wistar male rats by twice i.v. injection (tail vein) of alloxan (40 mg/kg body wt) with break of 48 hours. The rats were used in experiments at 6 th day from the first alloxan injection.
- Effect of the combination is 7.8 mmol/l decreasing in fasting plasma glucose level from the control.
- Effect of the combination is 4.1 ⁇ U/l decreasing in fasting plasma insulin level from the control.
- Bis(2-hydroxy-N,N,N-trimethylethanaminium) succinate is effective in treating insulin resistance, hyperlipidemia, dyslipidemia, and diabetes mellitus in diabetic rats.
- Diabetic rats were prepared as described in Example 1 of the invention.
- the animals were divided into two groups: a diabetic control group
- EXAMPLE 3 The process for producing bis(2-hydroxy-N,N,N-trimethylethanaminium) succinate.
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2000263274A AU2000263274A1 (en) | 2000-04-10 | 2000-04-10 | Synergistic compositions containing choline base and succinic acid for insulin resistance and diabetes |
PCT/RU2000/000122 WO2001076583A1 (en) | 2000-04-10 | 2000-04-10 | Synergistic compositions containing choline base and succinic acid for insulin resistance and diabetes |
CN00819413A CN1452482A (en) | 2000-04-10 | 2000-04-10 | Synergistic compositions contg. choline base and cuccinic acid for insulin resistance and diabetes |
KR1020027013553A KR20020089444A (en) | 2000-04-10 | 2000-04-10 | Synergistic compositions containing choline base and succinic acid for insulin resistance and diabetes |
CA002404864A CA2404864A1 (en) | 2000-04-10 | 2000-04-10 | Synergistic compositions containing choline base and succinic acid for insulin resistance and diabetes |
BR0017206-5A BR0017206A (en) | 2000-04-10 | 2000-04-10 | Synergistic compositions containing choline base and succinic acid for insulin resistance and diabetes |
JP2001574101A JP3944393B2 (en) | 2000-04-10 | 2000-04-10 | Synergistic composition comprising choline base and succinic acid for insulin resistance and diabetes |
EP00950127A EP1272171A1 (en) | 2000-04-10 | 2000-04-10 | Synergistic compositions containing choline base and succinic acid for insulin resistance and diabetes |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/RU2000/000122 WO2001076583A1 (en) | 2000-04-10 | 2000-04-10 | Synergistic compositions containing choline base and succinic acid for insulin resistance and diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001076583A1 true WO2001076583A1 (en) | 2001-10-18 |
Family
ID=20129496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2000/000122 WO2001076583A1 (en) | 2000-04-10 | 2000-04-10 | Synergistic compositions containing choline base and succinic acid for insulin resistance and diabetes |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1272171A1 (en) |
JP (1) | JP3944393B2 (en) |
KR (1) | KR20020089444A (en) |
CN (1) | CN1452482A (en) |
AU (1) | AU2000263274A1 (en) |
BR (1) | BR0017206A (en) |
CA (1) | CA2404864A1 (en) |
WO (1) | WO2001076583A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004093863A1 (en) * | 2003-04-24 | 2004-11-04 | Shin-Jen Shiao | A composition comprising an edible acid or its acidic salt and the use thereof |
WO2010062206A1 (en) * | 2008-11-26 | 2010-06-03 | Igor Anatolievich Pomytkin | Choline salts of succinic acid for the treatment of depression, anxiety, schizophrenia, sleep disorder, and epilepsy |
US8314080B2 (en) | 2010-04-06 | 2012-11-20 | Kuwait University | Method of treating type I diabetes |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100031760A (en) * | 2007-08-02 | 2010-03-24 | 부다 바이오파마 오와이 리미티드 | Pharmaceutical compositions for intranasal administration comprising choline salts of succinic acid |
CN106727476A (en) * | 2016-12-09 | 2017-05-31 | 杨远志 | A kind of composition and its application in animal muscle fiber types is improved |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2716M (en) * | 1962-02-12 | 1964-08-10 | Olin Mathieson | Stable compositions of choline ester salts. |
JPS61171417A (en) * | 1985-01-23 | 1986-08-02 | Wakunaga Seiyaku Kk | Antidiabetic |
WO2000051594A1 (en) * | 1999-03-01 | 2000-09-08 | Verteletsky, Pavel Vasilievich | Use of succinic acid or salts thereof and method of treating insulin resistance |
WO2000059499A1 (en) * | 1999-04-05 | 2000-10-12 | Verteletsky, Pavel Vasilievich | Use of succinic acid or salts thereof for the treatment of diabetes mellitus and wound healing |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6294520B1 (en) * | 1989-03-27 | 2001-09-25 | Albert T. Naito | Material for passage through the blood-brain barrier |
JPH03169498A (en) * | 1989-11-28 | 1991-07-23 | Yotsukaichi Gosei Kk | Water soluble flux for soldering |
JPH0586319A (en) * | 1991-09-27 | 1993-04-06 | Pentel Kk | Water-base ink composition |
US5895652A (en) * | 1996-07-29 | 1999-04-20 | Longevity Institute International | Method of metabolic adjuvanation and cellular repair |
-
2000
- 2000-04-10 CN CN00819413A patent/CN1452482A/en active Pending
- 2000-04-10 BR BR0017206-5A patent/BR0017206A/en not_active IP Right Cessation
- 2000-04-10 EP EP00950127A patent/EP1272171A1/en not_active Withdrawn
- 2000-04-10 KR KR1020027013553A patent/KR20020089444A/en not_active Application Discontinuation
- 2000-04-10 JP JP2001574101A patent/JP3944393B2/en not_active Expired - Fee Related
- 2000-04-10 AU AU2000263274A patent/AU2000263274A1/en not_active Abandoned
- 2000-04-10 CA CA002404864A patent/CA2404864A1/en not_active Abandoned
- 2000-04-10 WO PCT/RU2000/000122 patent/WO2001076583A1/en not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2716M (en) * | 1962-02-12 | 1964-08-10 | Olin Mathieson | Stable compositions of choline ester salts. |
JPS61171417A (en) * | 1985-01-23 | 1986-08-02 | Wakunaga Seiyaku Kk | Antidiabetic |
WO2000051594A1 (en) * | 1999-03-01 | 2000-09-08 | Verteletsky, Pavel Vasilievich | Use of succinic acid or salts thereof and method of treating insulin resistance |
WO2000059499A1 (en) * | 1999-04-05 | 2000-10-12 | Verteletsky, Pavel Vasilievich | Use of succinic acid or salts thereof for the treatment of diabetes mellitus and wound healing |
Non-Patent Citations (7)
Title |
---|
ANSERMINO J M ET AL: "SUXAMETHONIUM-INDUCED MUSCLE PAINS ARE NOT RELATED TO CHOLINESTERASE ACTIVITY", ANAESTHESIA,GB,ACADEMIC PRESS, LONDON, vol. 48, no. 12, December 1993 (1993-12-01), pages 1097 - 1100, XP000901320, ISSN: 0003-2409 * |
GLADYCH J M Z ET AL: "SYNTHETIC NEUROMUSCULAR BLOCKING AGENTS. PART IV. COMPOUNDS RELATED TO BOTH LAUDEXIUM AND SUXAMETHONIUM", JOURNAL OF THE CHEMICAL SOCIETY,GB,CHEMICAL SOCIETY. LETCHWORTH, 1962, pages 1481 - 1487, XP002070649 * |
KOREC ET AL: "Succinic acid alkyl esters-new genericoral anti-diabetic agents in alloxan and STZ diabetic rats", DIABETOLOGIA. SUPPLEMENT,DE,SPRINGER VERLAG, BERLIN, vol. 40, no. SUPPL. 01, June 1997 (1997-06-01), pages A375, XP002123539, ISSN: 0941-5602 * |
MACDONALD ET AL: "Glyceraldehyde phosphate and methyl esters of succinic acid. Two new potent insulin secretagogues", DIABETES,US,NEW YORK, NY, vol. 37, no. 7, July 1988 (1988-07-01), pages 997 - 999, XP002123535, ISSN: 0012-1797 * |
MALAISSE WILLY: "Insulinotropic Nutrient Esters", DRUGS OF THE FUTURE,ES,BARCELONA, vol. 23, no. 11, 1998, pages 1205 - 1216, XP002123537, ISSN: 0377-8282 * |
PATENT ABSTRACTS OF JAPAN vol. 010, no. 377 (C - 392) 16 December 1986 (1986-12-16) * |
See also references of EP1272171A1 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004093863A1 (en) * | 2003-04-24 | 2004-11-04 | Shin-Jen Shiao | A composition comprising an edible acid or its acidic salt and the use thereof |
WO2010062206A1 (en) * | 2008-11-26 | 2010-06-03 | Igor Anatolievich Pomytkin | Choline salts of succinic acid for the treatment of depression, anxiety, schizophrenia, sleep disorder, and epilepsy |
KR101360569B1 (en) | 2008-11-26 | 2014-02-10 | 이고르 아나토리에비치 포밋트킨 | Choline salts of succinic acid for the treatment of depression, anxiety, schizophrenia, sleep disorder, and epilepsy |
EA019584B1 (en) * | 2008-11-26 | 2014-04-30 | Игорь Анатольевич Помыткин | Choline salts of succinic acid for the treatment of depression, anxiety, schizophrenia, sleep disorder, and epilepsy |
US8314080B2 (en) | 2010-04-06 | 2012-11-20 | Kuwait University | Method of treating type I diabetes |
Also Published As
Publication number | Publication date |
---|---|
JP3944393B2 (en) | 2007-07-11 |
BR0017206A (en) | 2003-01-14 |
CA2404864A1 (en) | 2001-10-18 |
AU2000263274A1 (en) | 2001-10-23 |
KR20020089444A (en) | 2002-11-29 |
JP2004506605A (en) | 2004-03-04 |
CN1452482A (en) | 2003-10-29 |
EP1272171A1 (en) | 2003-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1284139B1 (en) | Novel fatty acid analogues for the treatment of fatty liver | |
US5132324A (en) | Use of 3-guanidinopropionic acid in the treatment of non-insulin dependent diabetes mellitus (niddm) | |
MX2009001104A (en) | Derivatives of 4-trimethylammonium-3-aminobutyrate and 4-trimethylphosphonium-3-aminobutyrate as cpt-inhibitors. | |
US20060148758A1 (en) | Method for blood glucose control in a mammal by N-acylated glucosamines | |
US8846745B2 (en) | Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels | |
EP1272171A1 (en) | Synergistic compositions containing choline base and succinic acid for insulin resistance and diabetes | |
EP2992888A1 (en) | Use of pentacyclic triterpenoid saponin compound from szechuan melandium root for preparing hypoglycemic drug | |
WO2002012177A1 (en) | Composition of metformin with succinic acid or salts thereof and method for treating diabetes | |
US9226905B2 (en) | Pharmaceutical composition for preventing or treating muscle wasting-related disease comprising diaminodiphenylsulfone or pharmaceutically acceptable salt thereof | |
WO2018166494A1 (en) | Use of matrine derivative in treatment of diabetes mellitus | |
US6509480B2 (en) | Glucose and lipid lowering compounds | |
US6521665B1 (en) | Method of treating insulin resistance | |
KR20010080428A (en) | Glucose and Lipid Lowering Compounds | |
RU2228174C2 (en) | Bis-(2=hydroxy-n,n,n-trimethylethaneaminium) succinate for treatment of insulin resistance, diabetes mellitus, hyperlipidemia and dyslipidemia | |
US5599841A (en) | Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders | |
EP4316486A1 (en) | Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative | |
Tursunov et al. | LIVER FUNCTION IN EXPERIMENTAL DIABETES MELLITUS AND WAYS OF ITS CORRECTION | |
CA2687154A1 (en) | Composition useful for the prevention of the adverse effect due to the use of ppar-gamma agonists | |
EP2768840A1 (en) | Anti-diabetic aminosteroid derivatives | |
WO2000028944A2 (en) | Use of succinic acid or salts thereof and method of treating insulin resistance |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2002 2002101481 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10181178 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027013553 Country of ref document: KR Ref document number: 008194130 Country of ref document: CN Ref document number: 2404864 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2001 574101 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000950127 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027013553 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2002/01289/MU Country of ref document: IN |
|
WWP | Wipo information: published in national office |
Ref document number: 2000950127 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000950127 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020027013553 Country of ref document: KR |